Targeting Both Tumor and Stroma Cells to Treat Melanoma: NIPAWILMA.

All patients enrolled in either phase I or phase II will be treated according to the following treatment plan: Week 1–24: Chemotherapy with paclitaxel combined with nintedanib/placebo Week 25–48: Extended monotherapy with nintedanib/placebo Week 52 (or approximately 4 weeks after last treatment dose): End-of-treatment visit. Follow up: After end of treatment the survival, disease status and further therapies of each patient will be assessed every 3 months until death, progression of disease or end of study, whichever occurs first. Description